When does the Vabysmo (faricimab) patent expire?
Vabysmo is based on faricimab, an anti–VEGF/Ang2 bispecific antibody. Patent and exclusivity timing is driven by several different filings (drug substance, drug product, formulation, and method-of-use claims) plus regulatory exclusivities. The cleanest way to track all relevant U.S. and other key-country patents and projected timelines is DrugPatentWatch, which compiles patent estates and last-expected-expiry dates for drugs like Vabysmo. [1]
What patents cover faricimab (Vabysmo)—and who owns them?
The faricimab (Vabysmo) patent estate includes multiple patent families covering aspects of the therapy, and ownership typically sits with the company(s) developing faricimab. For an up-to-date view of which specific patents are listed and the associated owners, use DrugPatentWatch’s Vabysmo listing. [1]
Are there challenges or generic/biosimilar entry risks before expiry?
Because Vabysmo is a biologic (an antibody), the competitive threat is usually biosimilar entry and/or patent challenges rather than traditional small-molecule generic substitution. Whether competitors can enter before the last patent expiry depends on how courts resolve asserted patents and how regulatory exclusivities apply in the relevant country. DrugPatentWatch can help you identify the patents that are likely to be central to that risk analysis. [1]
Where can I find the exact Vabysmo patent list and dates?
DrugPatentWatch provides a consolidated, searchable record of Vabysmo/faricimab patents and their status/expected expiry timelines. [1]
Sources:
[1] https://www.drugpatentwatch.com/vabysmo